Aurobindo Pharma Opens AuroSource To Offer CRAMS

Reportedly, AuroSource is expected to partner with pharma firms globally and cultivate opportunities to research, manufacture and develop compounds across the entire drug life cycle.

Aurobindo said that the division will deliver fully consolidated or customised manufacturing solutions for active pharmaceutical ingredients (APIs), intermediates, pre-formulations and formulations across each stage of the pharmaceutical life cycle.

Ramprasad Reddy, chairman of Aurobindo Pharma, said: “AuroSource is uniquely positioned to smoothly transition our competence in drug development to customers within this market segment. We stand to become an invaluable partner in enabling them to streamline and simplify their development and manufacturing processes so they can focus primarily on creating life-saving, low-cost products and contribute to making global healthcare more affordable.”

Sivakumaran, director on the board at Aurobindo Pharma, said: “By combining our research and development expertise with significant capability and facilities, our customers can securely outsource drug development projects while significantly reducing their need to absorb fixed costs around capital investments.

“AuroSource not only possesses the tools, expertise, assets and financial backing to support outsourcing efforts, but we also have a renewed commitment to optimize the internal selling processes in a seamless manner for our customers which include virtual and small biotech companies, mid-sized partially integrated companies and large vertically integrated companies.”